| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PCTK3; PCTAIRE; PCTAIRE3 |
| WB Predicted band size | 54 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human CDK18 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是模拟生成的关于CDK18抗体的参考文献示例(内容基于学术研究常见主题虚构，仅供参考)：
---
1. **"CDK18 modulates cell cycle progression through phosphorylation of RNA polymerase II"**
*作者：Smith A, et al.*
摘要：本研究利用CDK18特异性抗体，通过免疫沉淀和Western blot分析，揭示了CDK18通过磷酸化RNA聚合酶II C端结构域调控转录延伸，影响细胞周期G1/S期转换的机制。
2. **"CDK18 overexpression correlates with poor prognosis in triple-negative breast cancer"**
*作者：Zhang L, et al.*
摘要：通过免疫组化(IHC)结合抗CDK18抗体，研究发现在三阴性乳腺癌组织中CDK18表达显著升高，且与肿瘤转移和患者生存率降低相关，提示其作为潜在预后标志物。
3. **"Development and validation of a monoclonal antibody for detecting CDK18 in colorectal carcinoma"**
*作者：Tanaka K, et al.*
摘要：研究报道了一种高特异性抗CDK18单克隆抗体的开发，验证了其在结直肠癌组织与细胞系中的检测效果，并证实CDK18表达与5-FU化疗耐药性存在关联。
4. **"CDK18 interacts with cyclin K to promote transcriptional regulation in hepatocellular carcinoma"**
*作者：Wang X, et al.*
摘要：通过免疫共沉淀(Co-IP)和染色质免疫沉淀(ChIP)技术，结合CDK18抗体，揭示了CDK18与细胞周期蛋白K(Cyclin K)的相互作用，及其在肝癌细胞转录重编程中的促癌作用。
---
**注**：以上文献为模拟生成，旨在展示可能的抗体应用场景，实际研究中请通过学术数据库检索真实文献。
The cyclin-dependent kinase 18 (CDK18), a member of the CDK family, plays a role in regulating cell cycle progression and transcriptional modulation. It interacts with cyclins (e.g., cyclin E) to phosphorylate target proteins, influencing G1/S phase transition and DNA damage response pathways. CDK18 is implicated in cancer pathogenesis, with studies suggesting its dual role as either an oncogene or tumor suppressor depending on cellular context. Dysregulation of CDK18 has been linked to malignancies like breast cancer and glioblastoma, making it a potential therapeutic target.
CDK18 antibodies are essential tools for detecting and analyzing CDK18 expression and function in research. These antibodies are commonly used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study CDK18 localization, protein-protein interactions, and expression patterns in tissues or cell lines. Many commercially available CDK18 antibodies are raised against specific epitopes, often in the C-terminal region, and validated for species cross-reactivity (e.g., human, mouse). Researchers utilize these antibodies to explore CDK18's role in cell cycle control, cancer biology, and drug resistance mechanisms. Validation through knockout controls or siRNA knockdown is critical to confirm antibody specificity, given the structural similarities among CDK family members.
×
